In both control and tremor mice, administration of DPCPX reduced the amplitude threshold at which DBS produced involuntary movements, thereby demonstrating the capacity of adenosine to extend the ...

We have been exploring the potential of the neuromodulator, adenosine, to reduce excessive dopamine signaling that contributes to the development and persistence of psychostimulant abuse. Dopamine’s ...

Can-Fite BioPharma has secured a US patent for Namodenoson, its lead drug candidate, for use as an anti-obesity treatment. Set to be issued in February 2025, the patent will expire in 2042 and covers ...